Objective: To investigate the effect of Haishengsu, an extract from Tegillarca L. granosa, on the effects and side effects of immunotherapy in patients with advanced renal cell cancer. Methods: Fifty-five patients with renal cell cancer were randomly divided into Haishengsu (n=27, 2.4mg, iv for 15 days) and control group (n=28). All patients were also treated with interleukin-2 (IL-2), interferon-alpha (IFN) and fluorouracil (5-FU). Results: In the Haishengsu group, the prevalence of gastrointestinal reactions to the immunotherapy was lower than in the control group (18.5% vs 64.3%, P <0.01). In comparison with the control group, more patients from the Haishengsu group had increased food-intake (74.1% vs 14.3%, P<0.01), weight gain (77.8% vs 10.7%, P <0.01) or an increase in Karnofsky Performance Status (KPS) score (55.6% vs 17.9%, P<0.01). The remission rate of cancer in the Haishengsu group was higher than in the control group (51.9% and 21.4%, P <0.01). Conclusions: Addition of Haishengsu to the conventional immunotherapy is associated with an increased remission rate in patients with advanced renal cell cancer. Haishengsu was also associated with a reduced rate of gastrointestinal side effects from the immunotherapeutic agents, and an improved the physical functionality of the patients.
Liu, JZ., Chen, SG., Zhang, B., Wang, CB., Zhao, XW., Li, GY., & Wang, L. (2009). Effect of Haishengsu as an adjunct therapy for patients with advanced renal cell cancer: A randomized and placebo-controlled clinical trial. Journal of Alternative and Complementary Medicine, 15(10), 1127-1130. https://doi.org/10.1089/acm.2009.0260